IGF-1 LR3
Long R3 Insulin-Like Growth Factor — Anabolic Signaling
01
Overview
IGF-1 LR3 (Long R3 IGF-1) is a modified analogue of human insulin-like growth factor 1 featuring an arginine substitution at position 3 and a 13-amino-acid extension at the N-terminus. These modifications dramatically reduce binding to IGF-binding proteins, increasing bioavailability and half-life. It is studied for its potent anabolic and anti-catabolic effects on muscle, bone, and nervous tissue.
02
Mechanism of Action
IGF-1 LR3 binds the IGF-1 receptor (IGF-1R), activating the PI3K/Akt and MAPK/ERK pathways that drive protein synthesis, cell proliferation, and survival. The R3 and N-terminal extensions reduce affinity for IGFBP-3 and other binding proteins by approximately 100-fold, leaving more free peptide available for receptor engagement.
03
Research Highlights
Comparative binding studies confirm ~100-fold reduced IGFBP affinity versus native IGF-1
Muscle cell research demonstrates both hypertrophy (fiber growth) and hyperplasia (new fiber formation)
Neuroscience research shows protection against excitotoxic neuronal death via Akt signaling
04
Dosage
Administration & Timing
Subcutaneous (SC) injection into abdominal or gluteal subcutaneous tissue or Intramuscular (IM) injection, typically post-workout. Research protocols administer bilaterally into trained muscle region.
Dosage Guidelines
Cycle Length
4–8 weeks; cycle length capped due to receptor downregulation risk.
05
Reconstitution
Solvent
Reconstitute with acetic acid/HCl (0.6% acetic acid), then dilute with BW for injection
Volume
2 mL added to a 1 mg vial
Concentration
0.5 mg/mL (500 mcg/mL)
Storage
Lyophilized powder: store at -20 °C long-term. Reconstituted: refrigerate 2–8 °C, use within 30 days.
Notes
IGF-1 LR3 has an extended half-life vs native IGF-1 (~20 h). Requires acidic reconstitution — peptide is unstable in plain BW.
Research Reference Only
Dosage and reconstitution values reflect commonly cited ranges from published research literature and are presented for educational and research reference only. This is not medical advice or a dosing recommendation. HEXAGEN does not endorse human use of any compound. Always consult a qualified healthcare professional.
Research Disclaimer
IGF-1 LR3 is for educational and research purposes only. Not intended as medical advice. Consult a qualified healthcare professional before making any health-related decisions.
Related Compounds
View All
IGF-1 LR3 Knowledge Graph
Explore how IGF-1 LR3 connects to mechanisms, research goals, related compounds, research stacks, and scientific references. Drag nodes, zoom, and filter by type.
No nodes match the active filters.
IGF-1 LR3 — Common Research Questions
What is IGF-1 LR3?
IGF-1 LR3 (Long R3 IGF-1) is a modified analogue of human insulin-like growth factor 1 featuring an arginine substitution at position 3 and a 13-amino-acid extension at the N-terminus. These modificat... IGF-1 LR3 belongs to the Other research category and is studied for its long r3 insulin-like growth factor — anabolic signaling.
How does IGF-1 LR3 work?
IGF-1 LR3 binds the IGF-1 receptor (IGF-1R), activating the PI3K/Akt and MAPK/ERK pathways that drive protein synthesis, cell proliferation, and survival. The R3 and N-terminal extensions reduce affinity for IGFBP-3 and other binding proteins by approximately 100-fold, leaving more free peptide available for receptor engagement.
What are the key research benefits of IGF-1 LR3?
Potent anabolic signaling through IGF-1R. Reduced IGF-binding protein affinity for extended bioavailability. Muscle hypertrophy and hyperplasia in research. Neuroprotective and neurotrophic effects. Cartilage and bone formation stimulation. Anti-catabolic protection during caloric deficit.
What is the molecular structure of IGF-1 LR3?
IGF-1 LR3 is a research compound in the Other category. Detailed molecular structure data is being compiled. Refer to primary literature for structural analysis.
What does the research say about IGF-1 LR3?
Comparative binding studies confirm ~100-fold reduced IGFBP affinity versus native IGF-1 Muscle cell research demonstrates both hypertrophy (fiber growth) and hyperplasia (new fiber formation) Neuroscience research shows protection against excitotoxic neuronal death via Akt signaling These findings are based on preclinical and clinical research. IGF-1 LR3 is a research compound and these studies do not constitute medical advice.
Is IGF-1 LR3 FDA approved?
No. IGF-1 LR3 is not FDA-approved for any indication. It is a research chemical studied in preclinical and early clinical research. These compounds are not approved for human therapeutic use and should only be studied in appropriate research settings.
What category does IGF-1 LR3 belong to?
IGF-1 LR3 belongs to the Other category, which focuses on a collection of specialized peptides studied across various physiological domains including reproductive health, pigmentation, and growth factor signaling. You can explore more compounds in this category on the Other pillar page.
Related Articles
PT-141: Central Nervous System Activation of Sexual Desire
Understanding how PT-141 differs from PDE5 inhibitors and its Phase III HSDD clinical trial data.
DSIP: Delta Sleep-Inducing Peptide
The discovery, mechanism, and stress-modulation research behind DSIP's sleep-promoting effects.
Kisspeptin: The Gatekeeper of the HPG Axis
How Kisspeptin's pulsatile signaling controls GnRH release and its implications for reproductive research.
Scientific References
Comparative binding studies confirm ~100-fold reduced IGFBP affinity versus native IGF-1
Muscle cell research demonstrates both hypertrophy (fiber growth) and hyperplasia (new fiber formation)
Neuroscience research shows protection against excitotoxic neuronal death via Akt signaling